Urinary Profiles of the Endogenous Steroids in Pre-Menopausal Women with Uterine Leiomyoma by 김세광 & 배상욱
- 23 -
大 韓 不 妊 學 會 誌 : 第 30 卷  第 1 號  2003
Kor. J. Fertil. Steril., Vol. 30, No. 1, 2003, 3
Urinary Profiles of the Endogenous Steroids in Pre-Menopausal
Women with Uterine Leiomyoma
Byung Hwa Jung1, Sang Wook Bai2, Bong Chul Chung1, Sei Kwang Kim2,
Ki Hyun Park2
1Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology,
2Department of Obstetrics and Gynecology, College of Medicine, Yonsei University, Seoul, Korea
자궁근종 성장에 있어서 내인성 성호르몬의 역할
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목 적: 본 연구의 목적은 내인성 성호르몬이 자궁근종의 성장에 미치는 영향을 알아보고자 연구를
시행하였다.
연구대상 및 방법: 폐경전 자궁근종 환자 27명과 같은 연령대의 정상여성 25명을 대상으로 하였다.
모든 대상군의 여성에서 24시간 소변을 모아서 소변내 estrogen, androgen의 대사체들을 GC-MS를 이용
하여 측정하였으며 두 군에서의 차이를 비교분석 하였다.
결 과: 소변내 17ß-estradiol, 5-androstene-3ß, 16ß, 17ß-triol, 11-keto-ethiocholanolone, 11ß-hydroxy -
androsterone, THS, THA, THE, a-cortolone, a-cortol 및 ß-cortol가 환자군에서 의의있게 증가하였으며 17ß-
estradiol/estrone 및 11ß-hydroxy-ethiocholanolone/11ß-hydroxy-androsterone도 환자군에서 의의있게 증가하
였다.
결 론: 자궁근종의 성장은 요중 estrogen과 androgen의 농도와 밀접한 관련이 있으며 이는 환자의
스테로이드 호르몬 대사 감소에 기인한 것으로 사료된다.
중심단어: 자궁근종, 스테로이드, 에스트로젠, 안드로젠, 요중농도
Uterine leiomyoma is the most common solid
pelvic tumor, occurring in 20~30% of women
who are over 30 years of age1 and it accompanies
with the symptoms such as uterine bleeding, dys-
menorrhea, pain and the pressure on the urinary
tract lead to blockage of the urinary tract. It some-
times becomes a factor in sterility.2 Leiomyoma is
a benign neoplasm that arises from uterine smooth
muscle. It is hypothesized that leiomyoma origi-
nates from the somatic mutations in myometrial
cells, resulting in progressive loss of growth-
regulation.3,4
Ovarian hormones are believed to stimulate the
growth of leiomyoma because there is an increased
incidence of leiomyoma after menarche and these
tumors enlarge during pregnancy and regress after
menopause. The growth of leiomyoma is variable
among women with regular menstruation cycles
and even among myoma nodules in the same
uterus. One possible reason for this variation is that
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ovarian hormones, especially estrogen, stimulate
individual myoma nodules by varying degree.5
Therefore, therapeutic attempt based on over-
come the state of hyperestrogenism have been tried.
Treatment with competitive inhibitors of estrogen
receptors (ER)6,7 or gonadotropin-releasing hor-
mone agonist2,8,9 has been studied for those reasons.
It was found that mean ER content was signifi-
cantly greater in leiomyoma than in myometrium.
10~14 And ER content of the fibroid was reported to
significantly correlate with the myoma-shrinkage.15
But there were no consistent results as the concen-
tration of estrogen in uterine leiomyoma.16,17
In this study, we determined the concentrations
of urinary steroids, including estrogens as well as
androgens, which are closely related to the estro-
gen biosynthesis, in premenopausal women with
leiomyoma using Gas Chromatography-Mass Sp-
ectrometry (GC-MS). The urinary levels of the
same endogenous steroids in age-matched healthy
premenopausal women were also estimated by
comparing urinary steroid levels between the two
groups.
From these results, we studied the effect of
endogenous steroids and the metabolic changes in
the leiomyoma, and we especially observed the
difference in the estrogen level between the two
groups to predict the role of estrogens in the pre-
vention of and the therapy for leiomyoma.
MATERIALS AND METHODS
1. Materials
Androgen and estrogen standards were purcha-
sed from Sigma (St. Louis, Mo, USA). d2-17ß-
estradiol used as an internal standard for the estro-
gen profile was purchased from MSD Isotope
(Montreal, Canada). All reagents were of analytical
grade and were used without additional purifica-
tion. Serdolit AD-2 resin (particle size: 0.1~0.2
mm) was purchased from Serva (Heidelberg, Ger-
many). ß-glucuronidase/arylsulfatase from Helix
Pomatia was purchased from Boeringer Mann-
heim (Germany). ß-glucuronidase activity was 5.5
U/ml (at 39℃) and aryl sulfatase activity was 2.6
U/ml (at 38℃). Silylating reagents, MSHFB (N-
methyl-N-trimethylsilyheptafluorobutyramide) was
purchased from Machery-Nagel (Duren, Germany),
and MSTFA (N-methyl-N-trimethylsilyltrifluoro-
acetamide), TMCS (trimethylsilylchloride), and
TMSIm (N-trimethylsilylimidazole) was purchased
from Sigma (St. Louis, MO, USA). Ethylacetate
and ether were of a high purity "HPLC solvent"
grade, and ether was distilled before use.
2. Subjects and sample collection
The subjects consisted of pre-menopausal women
with uterine leiomyoma (n=27, patients) and heal-
thy, pre-menopausal women with no evidence of
myoma (n=25, controls). All patients underwent
pelvic and ultrasound exams, and the presence of
the myoma was confirmed by surgical pathology.
All subjects were in the late luteal phase of men-
strual cycle. The ages of the women were 43.1±
5.6 and 39.6±7.2 years old, the weights 61.4±7.3
and 54.9±8.1 kg, and the heights 159.3±8.3 and
155.1±4.8 cm in the patients and in controls, res-
pectively. They were all Korean and nonsmokers.
The urine samples were colleted for 24 hrs, and the
urine samples were stored at -20℃ until analysis.
The creatinine value for each sample was measu-
red by the Jaffé method.
3. Gas Chromatography-Mass
Spectrometry
The Hewlett-Packard GC-MS system consisted
of a gas chromatography (HP 5972) and mass
spectrometry (HP 5989B mass engine). The GC
column used for the analysis of estrogens was a
fused-silica capillary coated with cross-linked 5%
phenylmethyl siloxane (length: 25 m; inner dia-
meter: 0.2 mm; film thickness: 0.33 µm). For the
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analysis of androgens, a fused silica capillary, coa-
ted with phenylmethylsiloxane (length: 17 m; inner
diameter: 0.2 mm; film thickness: 0.11 µm) was
used. Helium was used as a carrier gas (the flow
rate was 0.85 ml/min), and the split ratio was 1:10.
The GC temperature program was as follows. In
the case of estrogens, the initial temperature of
180℃ was increased to 260℃ at a rate of 20℃
/min and maintained for 6 min, then the tempera-
ture was increased to 275℃ at a rate of 2℃/min
and maintained for 8 min. Finally, it was increased
to 300℃ at a rate of 15℃/min and maintained for
10 min. And for androgens, the initial temperature
(180℃) was programmed at 4℃/min to 300℃
and maintained for 2 min. The injector tempera-
ture was 300℃, the transfer line was 300℃ and
the ion source was 200℃. The mass spectrometer
was operated at 70 eV in the electron-impact (EI)
mode. The selected ion-monitoring (SIM) mode
was used for quantifying the 20 estrogens and the
21 androgens. The dwell time for each ion was set
at 50 msec.
4. Extraction of estrogens  and androgens
A preconditioned Serdolit AD-2 resin was pou-
red into a pasteur pipette (inner diameter-0.5 cm)
to 3 cm. The urine sample (3 ml) and internal
standard (d 2-17ß-estradiol, 1.5 µg for estrogens
and methyl testosterone, 5 µg for androgens) were
applied to the column. After the column was was-
hed with 3 ml of water, the free and conjugated
endogenous steroids were eluted three times with
1 ml of methanol. The eluent was evaporated to
dryness in a rotary evaporator. Enzyme hydrolysis
was performed using ß-glucuronidase/arylsulfatase
(from Helix Pomatia) with 1 ml of acetate buffer
(0.2 N, pH 5.0) at 55℃ for 3 hrs. To prevent the
oxidation of catechol estrogens, ascorbic acid (1
mg/ml) was added at the hydrolysis of estrogens.
After hydrolysis, potassium carbonate was added,
and the pH was adjusted to 9.0. The mixture was
extracted with 5 ml of ethyl acetate for estrogens
and 5 ml of ether for androgens, respectively. The
organic layer was transferred to another tube and
dried using a vacuum evaporator. The residue was
dried in a vacuum desiccator over P2O5/KOH in
order to complete removal of moisture. The residue
was derivatized with the derivatizing reagents to
improve the detection in GC-MSD. The deriva-
tization was performed by using the mixture of
MSTFA/TMCS (100:1, volume ratio) at 60℃ for
30 min for estrogens and MSHFB/TMCS/TMSIm
(2:2:1, volume ratio) at 60℃ for 10 min for andro-
gens. After cooling, 2 µl of the aliquots was in-
jected into the GC column  by an auto sampler.
5. Assay
The following 18 estrogens (estrone [E1], 17ß-
estradiol [E2], 2-hydroxyestrone [2-OH E1], 2-
hydroxyestradiol, 2-methoxyestrone [2-Meo E1],
17a-estradiol, 6-dehydroestrone, 6a-hydroxyestra-
diol, 4-methoxyestradiol, estriol [E3], 16-epiestriol
[16-Epi E3], 16, 17-epiestriol, 16a-hydroxyestrone
[16a-OH E1], 17-epiestriol, 6-ketoestriol, 2-me-
thoxyestriol, 6-hydroxyestriol, and 16-ketoestra-
diol [16-Keto E2]) and 24 androgens (androgen
[An], etiocholanolone [Et], dehydroepiandrosterone
[DHEA], 4-androstenedione [? 4-dione], testoste-
rone [Te], dihydrotestosterone [DHT], 5-andro-
stenediol [? 5-diol], 11ß-hydroxy An [11ß-OH An],
11ß-hydroxy Et [11ß-OH Et], 11-keto An, 11-keto
Et, tetrahydrodeoxycorticosterone [THDOC], 16a-
hydroxy DHEA [16a-OH DHEA], 5-androstene-
3a, 16ß, 17ß-triol [5-AT], tetrahydro-11-deoxy-
cortisol [THS], tetrahydrocortisone [THE], 5a-
tetrahydrocortisol [5a-THF], 5ß-tetrahydrocortisol
[THF], a-cortolone, ß-cortolone, a-cortol, ß-cortol,
5a-tetrahydrocorticosterone [5a-THB] and 5ß-
tetrahydrocorticosterone [THB]) were determined.
All values were corrected by concentration of uri-
nary creatinine.
All urine samples were analyzed in separate
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batches for the two groups within a month period
together with one duplicate quality-control sample
for each batch. The quality-control samples used
were pooled urine samples from normal indivi-
duals.
The recovery range of the extraction of andro-
gens was 72.3~94.5%. The CVs (coefficient of
variances) of intraday analysis was 1.42~10.86%
and that of interday analysis was 0.96~9.98%.18 In
regard to the extraction for estrogens, the reco-
very range was 81.0~97.8% and the CVs of in-
traassay and interassay were 1.05~10.24% and
0.24~10.52%, respectively.19 This result appro-
ved that the analytical methods used in this study
were reliable for the determination of the urinary
steroids.
6. Statistical analysis
Statistical analysis for the level of significance
was conducted by the t-test for two independent
means using the SAS system for windows V9.00
(SPSS Institute Inc. IL, Chicago, USA).
RESULTS
1. Profiles  of estrogens
Estrone and 17ß-estradiol were detected in all
subjects (both of patients with leiomyoma and
controls). Table 1 shows the concentrations of
estrone and 17ß-estradiol. Trace amounts of hy-
droxylated and methoxylated metabolites, such as
estriol and 2-methoxyestrone, were detected in the
Table 2. Concentrations (µmole/g creatinine, mean ± SD) of urinary androgens in normal female subjects (controls,
n=25) and patients (patients, n=27) with uterine leiomyoma
Compounds Controls Patients p value
Androsterone (An) 1.05±0.45 1.26±1.26 NS
Etiocholanolone (Et) 0.96±0.41 1.04±1.08 NS
5-Androstene-3ß, 16ß, 17ß-triol (5-AT) 0.26±0.10 1.06±0.94 p<0.01
11-keto Et 0.32±0.18 0.98±1.38 p<0.05
11ß-hydroxy An 0.69±0.29 1.25±1.11 p<0.05
11ß-hydorxy Et 0.29±0.12 1.22±1.87 p<0.05
Tetrahydro-11-deoxycortisol (THS) 0.27±0.10 0.61±0.63 p<0.05
Tetrahydro-11-dehydrocorticosterone (THA) 0.40±0.13 1.72±1.55 p<0.05
Tetrahydrocortisone (THE) 10.0±5.07 3.19±4.35 p<0.01
5ß-Tetrahydrocortisol (THF) 1.25±0.75 2.16±3.75 NS
a-cortolone 2.16±0.79 3.37±4.05 p<0.05
ß-cortolone 2.14±1.27 0.94±0.71 NS
a-cortol 0.60±0.22 1.11±1.06 p<0.05
ß-cortol 0.12±0.31 1.64±1.92 p<0.01
5a-THB 0.55±0.14
5a-THF 0.56±0.08
Table 1. Concentrations (nmole/g creatinine, mean ±
SD) of urinary estrogens in normal female subjects
(controls, n=25) and patients (patients, n=27) with
uterine leiomyoma
Compounds Control Patient p value
Estrone 22.8±8.81 22.9±10.2 NS
17ß-estradiol 20.8±4.46 29.4±11.1 <0.05
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urine of controls and patients, but it is impossible
to quantify the findings due to the low level, which
was below detection limits.
The urinary concentration of estradiol was sig-
nificantly higher (p<0.05) in the patients with leio-
myoma than in controls but the concentration of
estrone was not significantly different between the
two groups. The mean E2/E1 ratio was significan-
tly higher (p<0.01) in the patients with leiomyoma
than in controls (Table 3).
2. Profile of Androgens
The urinary concentrations of androgens are
presented in Table 2. DHEA, ? 4-dione, ? 5-diol, Te,
DHT, 16a-OH DHEA, 11-keto An, THDOC, 5a-
THF, THB, and 5a-THB were not detected in the
urine of neither controls nor patients. But 5-AT,
11-keto Et, 11ß-OH An, 11ß-OH Et, THS, THA,
THE, a-cortolone, a-cortol and ß-cortol were sig-
nificantly higher in the patients with leiomyoma
than controls. The urinary concentration ratio of
11ß-hydroxy-ethiocholanolone/11ß-hydroxy-andro-
sterone increased in the patients with leiomyoma,
however, there was no significant difference in the
urinary concentration ratio of Et/An between the
two groups.
DISCUSSION
Uterine leiomyoma is a tumor closely related
the estrogen and it has been noted that the deve-
lopment of leiomyoma depends on the condition
of menstruation, for example pre-, postmenopause,
and pregnancy. It was also found that estrogen rece-
ptors increased in leiomyoma when compared with
the myometrium in the patients with leiomyoma,
10~14,17 but some contrary results were reported on
the concentration of estrogens.
Otubu JA et al.,15 Potgieter HC et al.16 and Wu J
et al.17 found that the concentration of 17ß-estradiol
was significantly higher in leiomyoma than normal
myometrium. On the other hand, Potgieter HC et
al.16 also reported that the serum estrogen level did
not differ significantly between the patients with
leiomyoma and normal subjects.
After the GC-MS determination of urinary endo-
genous steroids in this study, the urinary concen-
trations of 17ß-estradiol was significantly higher in
the patients  with leiomyoma than controls.
This finding does not correspond to the result of
Potgieter HC et al.16 considering that the urinary
level is  a reflection of the plasma level.
It is thought that increase of 17ß-estradiol is
closely related to the significant increase of E2/
E1 ratio (p<0.05) in the patients with leiomyoma
(Table 3). Because 17ß-estradiol is converted to
estrone through the oxidation by 17ß-hydroxy ster-
oid dehydrogenase, it means that metabolic change
in the conversion of 17ß-estradiol to estrone signi-
ficantly decreased in the patient with leiomyoma.
This result agrees with the results of Pollow K et
al.20
In the urinary levels of androgens, 5-AT, 11-keto
Et, 11ß-OH An, 11ß-OH Et, THS, THA, THE, a -
cortolone, a-cortol and ß-cortol were significantly
higher in the patients with leiomyoma than con-
trols.
Androgens are known to be the precursors of
Table 3. Concentration ratios (mean ± SD) of etiocholanolone to androsterone (Et/An), 11ß-OH etiocholanolone to 11ß-
OH androsterone (11ß-OH Et/11ß-OH An) and estradiol to estrone (E2/E1) in normal female subjects (controls, n=25)
and patients with leiomyoma (n=27)
Concentration ratio Controls Patients p value
Et/An 1.12±0.34 0.95±0.38 NS
11ß-OH Et/11ß-OH An 0.45±0.35 0.84±0.76 <0.05
E2/E1 0.89±0.78 2.01±1.60 <0.01
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estrogens in biosynthesis. Actually, androstenedi-
one was metabolized by the human endometrium,
myometrium and leiomyomata in vitro,21 and aro-
matase inhibitor, 14a-hydroxy-4-androstene-3, 6,
17-trione (new androstenedione derivative), inhibits
estrogen biosynthesis  in human uterine tumors.22
For that reason, urinary concentrations of andro-
gens were determined in this study, and the activity
of 5a-reductase was examined by the urinary con-
centration ratios of Et/An and 11ß-OH Et/11ß-OH
An.
Similar to the results of estrogens, the concen-
tration ratio of 11ß-OH Et/11ß-OH An was higher
in the patients with leiomyoma than controls. Ho-
wever, there was no significant difference in the
urinary concentration ratio of Et/An. This indicates
that androgens metabolism also partially decreased
in the disease state of leiomyoma.
In conclusion, it is thought that the growth of
uterine leiomyoma correlates with the increase of
the urinary level of estrogen and androgen, and
this seems to be caused by the decrease of steroid
metabolism in the patients with leiomyoma.
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